RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
Wall Street Falls as Treasury Yields Surge, Oil Rebounds on Iran Tensions 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
Fed Unveils Stablecoin Rules Under GENIUS Act 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
US, China Extend Trade Truce to Jan. 10 Ahead of Trump-Xi Summit 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
Add as a preferred source on Google
Philips announced that it has started the repairs and replacements of its first-generation respiratory devices that were recalled in the United States. The healthcare unit of the Dutch multinational conglomerate will be addressing the issues in the recalled DreamStation devices numbering to millions.
Based on the recall notice, it was stated that the recalled machines pose potential health risks so customers were immediately told to stop using the affected model units of Philip’s respiratory machines. As Reuters reported, the U.S. Food and Drug Administration (FDA) announced a recall on some models of DreamStation respiratory and ventilator devices in June.
They were found to have become toxic over time as the foam part might deteriorate. When this happens, the machines may potentially cause cancer. Philips received authorization from the FDA to allow rework in the affected units that could reach four million in total.
Almost half of the affected respiratory machines were sold in the U.S. so the latest recall notification is for this country only at this time. For the rest of the world, Philips has issued a field safety notice for the issue which the FDA classified as Class I recall. In any case, the company said that it will take them about a year to replace or repair the machines.
“We fully recognize that the timeframe for remediation of the affected devices places patients in a difficult situation,” Royal Philips’ chief executive officer, Frans van Houten, said in a press release. “We are mobilized to deliver a solution to them as fast as possible. We have significantly increased our production, service and rework capacity, and further intensified our outreach to our customers and their patients.”
The CEO is also urging patients who are using the affected devices to register their units on the website dedicated for the recalls. This will help them with the process of tracking and obtaining details about the machines.
Aside from the ongoing repairs and replacements, Philips continues to communicate with the FDA to address any other details of the recall as well as mitigation plans in the country. The company has reserved $590 million for the recall operation this year.
